<- Go Home
Tilray, Inc. prior to merger with Aphria Inc.
As of April 30, 2021, Tilray, Inc. prior to merger with Aphria Inc. was acquired by Tilray, Inc., in a reverse merger transaction. Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, clinics, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, Germany, Israel, New Zealand, Portugal, Spain, Africa, Switzerland, the United States, Malta, and the United Kingdom. The company was incorporated in 2018 and is based in Nanaimo, Canada.
Market Cap
$2.9B
Volume
19.4M
Cash and Equivalents
$416.4M
EBITDA
-$97.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$27.8M
Profit Margin
14.84%
52 Week High
$67.00
52 Week Low
$4.41
Dividend
N/A
Price / Book Value
5.64
Price / Earnings
-5.64
Price / Tangible Book Value
16.45
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$116.0M
Return on Equity
117.08%
Return on Assets
-6.96
Cash and Short Term Investments
$425.7M
Debt
$343.9M
Equity
$540.6M
Revenue
$187.6M
Unlevered FCF
$13.1M
Sector
Pharmaceuticals
Category
N/A